Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Enters $95 Million Agreement to In-License Gout Treatment

publication date: Dec 15, 2022

Suzhou Innovent in-licensed China rights to a gout treatment from Korea’s LG Chem Life Science in a $95 million agreement. LG Chem's Tigulixostat is a novel non-purine xanthine oxidase inhibitor aimed at management of chronic hyperuricemia in gout disease patients. In a US Phase II trial, the candidate showed efficacy for sUA lowering and a good safety profile as a first-line therapy. Innovent will make a $10 million upfront payment to LG Chem, and it will be responsible for $85.5 million in milestones, plus royalties. More details....

Stock Symbol: (HKEX: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital